Endsulin LLC, based in Madison, WI, is a pioneering biotech company focused on developing a groundbreaking genetic therapy for Type 1 Diabetes. Founded by a world-renowned scientist and transplant surgeon, the company aims to revolutionize diabetes treatment by re-engineering liver cells to enable the body to produce and regulate its own insulin.
With a mission to provide long-term relief from the burden of artificial insulin dependence, Endsulin's innovative approach seeks to offer patients a single infusion treatment without the need for immunosuppressive agents. Through years of university research and a team of leading experts in gene therapy and regulatory affairs, Endsulin is dedicated to realizing the goal of freeing diabetes patients from the constraints of traditional insulin management.
Generated from the website